Scholarlink

Background <p>Diarrhea represents a frequent complication in pediatric patients with bronchopneumonia. This study was designed to identify independent risk factors for diarrheal complications and to propose evidence-informed nursing interventions.</p> Methods <p>A retrospective cohort study was conducted among 280 hospitalized children with bronchopneumonia. Demographic, anthropometric, laboratory, and treatment-related data were extracted from electronic medical records. Multicollinearity was assessed by variance inflation factor (VIF), and independent risk factors were identified through binary logistic regression with model fit evaluated by the Hosmer–Lemeshow test.</p> Results <p>The incidence of diarrhea was 23.57%. Eight independent risk factors were identified: antibiotic duration ≥ 7 days (OR = 3.006), β-lactamase inhibitor combination use (OR = 2.916), combined antibiotic use (OR = 2.401), mixed pulmonary infection (OR = 2.105), age &lt; 5 years (OR = 2.048), weight-for-height/length z-score &lt; − 2 (OR = 1.982), serum albumin &lt; 35&#xa0;g/L (OR = 1.896), and C-reactive protein ≥ 20&#xa0;mg/L (OR = 1.845). Probiotic administration was an independent protective factor (OR = 0.849). All VIF values were &lt; 5, and the Hosmer–Lemeshow test indicated adequate model fit (<i>P</i> &gt; 0.05).</p> Conclusion <p>Diarrhea in children with bronchopneumonia is associated with multiple clinical and therapeutic variables, with β-lactamase inhibitor combinations and prolonged antibiotic therapy conferring the highest risk. These findings provide a hypothesis-generating foundation for risk-stratified nursing strategies to reduce diarrheal complications. However, given the retrospective design and the inability to distinguish antibiotic-associated diarrhea from infectious diarrhea, the identified associations should be interpreted cautiously, and any derived clinical recommendations require prospective validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Occurrence of diarrhea in pediatric bronchopneumonia patients: relevance to nursing management

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月11日

查看全文
  • Yinyan Tang,
  • Qian Zhang,
  • Tingting Yu

摘要

Background

Diarrhea represents a frequent complication in pediatric patients with bronchopneumonia. This study was designed to identify independent risk factors for diarrheal complications and to propose evidence-informed nursing interventions.

Methods

A retrospective cohort study was conducted among 280 hospitalized children with bronchopneumonia. Demographic, anthropometric, laboratory, and treatment-related data were extracted from electronic medical records. Multicollinearity was assessed by variance inflation factor (VIF), and independent risk factors were identified through binary logistic regression with model fit evaluated by the Hosmer–Lemeshow test.

Results

The incidence of diarrhea was 23.57%. Eight independent risk factors were identified: antibiotic duration ≥ 7 days (OR = 3.006), β-lactamase inhibitor combination use (OR = 2.916), combined antibiotic use (OR = 2.401), mixed pulmonary infection (OR = 2.105), age < 5 years (OR = 2.048), weight-for-height/length z-score < − 2 (OR = 1.982), serum albumin < 35 g/L (OR = 1.896), and C-reactive protein ≥ 20 mg/L (OR = 1.845). Probiotic administration was an independent protective factor (OR = 0.849). All VIF values were < 5, and the Hosmer–Lemeshow test indicated adequate model fit (P > 0.05).

Conclusion

Diarrhea in children with bronchopneumonia is associated with multiple clinical and therapeutic variables, with β-lactamase inhibitor combinations and prolonged antibiotic therapy conferring the highest risk. These findings provide a hypothesis-generating foundation for risk-stratified nursing strategies to reduce diarrheal complications. However, given the retrospective design and the inability to distinguish antibiotic-associated diarrhea from infectious diarrhea, the identified associations should be interpreted cautiously, and any derived clinical recommendations require prospective validation.